二甲双胍与磺脲类对糖尿病合并肾功能减退患者主要不良心血管事件的影响比较
该回顾性队列研究纳入美国退伍军人健康管理局174 882例持续使用二甲双胍或磺脲类单药治疗、并达到肾功能减退阈值(eGFR<60 mL/min/1.73 m2或肌酐女性≥1.4 mg/dL、男性≥1.5 mg/dL)的糖尿病患者。经倾向评分加权后比较24 679例二甲双胍与24 799例磺脲类使用者,主要终点为主要不良心血管事件(MACE,包括急性心肌梗死、卒中、短暂性脑缺血发作住院或心血管死亡)。二甲双胍组MACE发生率为23.0/1000人年,磺脲类组为29.2/1000人年,校正病因特异性HR为0.80(95%CI 0.75-0.86),校正率差为每1000人年减少5.8例事件(95%CI 4.1-7.3)。作者认为,在持续单药治疗的糖尿病合并肾功能减退患者中,二甲双胍相比磺脲类与较低的MACE风险相关。
要点
- 在持续单药治疗的糖尿病合并肾功能减退(eGFR<60 mL/min/1.73 m2或肌酐女性≥1.4 mg/dL、男性≥1.5 mg/dL)患者中,二甲双胍相比磺脲类的校正MACE HR为0.80(95%CI 0.75-0.86)。
- 二甲双胍组MACE发生率为23.0/1000人年,磺脲类组为29.2/1000人年,校正率差为每1000人年减少5.8例事件(95%CI 4.1-7.3)。
- 加权队列中位年龄70岁(IQR 62.8-77.8),98%为男性,82%为白人,队列进入时中位eGFR 55.8 mL/min/1.73 m2(IQR 51.6-58.2),中位HbA1c 6.6%(IQR 6.1%-7.2%)。
- 随访中位时间二甲双胍组1.0年、磺脲类组1.2年,期间共记录二甲双胍组1048例MACE、磺脲类组1394例MACE。
适用人群与场景
- 美国退伍军人健康管理局内持续使用二甲双胍或磺脲类单药治疗、并达到肾功能减退阈值(eGFR<60 mL/min/1.73 m2或肌酐女性≥1.4 mg/dL、男性≥1.5 mg/dL)的糖尿病患者。
- 研究纳入2001年至2016年数据,随访至MACE、治疗改变、失访、死亡或研究结束(2016年12月)。
诊断标准与关键阈值
- 肾功能减退阈值:估计肾小球滤过率<60 mL/min/1.73 m2,或肌酐女性≥1.4 mg/dL、男性≥1.5 mg/dL。
- MACE定义:因急性心肌梗死、卒中、短暂性脑缺血发作住院或心血管死亡。
研究设计与关键结果
- 回顾性队列研究,纳入174 882例持续新使用二甲双胍或磺脲类并达到肾功能减退阈值的糖尿病患者;倾向评分加权队列包含24 679例二甲双胍和24 799例磺脲类使用者。
- 加权队列中位年龄70岁(IQR 62.8-77.8),48 497例男性(98%),40 476例白人(82%),队列进入时中位eGFR 55.8 mL/min/1.73 m2(IQR 51.6-58.2),中位HbA1c 6.6%(IQR 6.1%-7.2%)。
- 随访中位时间二甲双胍组1.0年 vs 磺脲类组1.2年;二甲双胍组1048例MACE(23.0/1000人年) vs 磺脲类组1394例MACE(29.2/1000人年)。
- 二甲双胍相比磺脲类的校正病因特异性MACE HR为0.80(95%CI 0.75-0.86),校正率差为每1000人年减少5.8例事件(95%CI 4.1-7.3)。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在持续单药治疗的糖尿病合并肾功能减退患者中,二甲双胍相比磺脲类与较低的MACE风险相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Before 2016, safety concerns limited metformin use in patients with kidney disease; however, the effectiveness of metformin on clinical outcomes in patients with reduced kidney function remains unknown.
OBJECTIVE: To compare major adverse cardiovascular events (MACE) among patients with diabetes and reduced kidney function who continued treatment with metformin or a sulfonylurea.
DESIGN, SETTING, AND PARTICIPANTS: Retrospective cohort study of US veterans receiving care within the national Veterans Health Administration, with data supplemented by linkage to Medicare, Medicaid, and National Death Index data from 2001 through 2016. There were 174 882 persistent new users of metformin and sulfonylureas who reached a reduced kidney function threshold (estimated glomerular filtration rate <60 mL/min/1.73 m2 or creatinine ≥1.4 mg/dL for women or ≥1.5 mg/dL for men). Patients were followed up from reduced kidney function threshold until MACE, treatment change, loss to follow-up, death, or study end (December 2016).
EXPOSURES: New users of metformin or sulfonylurea monotherapy who continued treatment with their glucose-lowering medication after reaching reduced kidney function.
MAIN OUTCOMES AND MEASURES: MACE included hospitalization for acute myocardial infarction, stroke, transient ischemic attack, or cardiovascular death. The analyses used propensity score weighting to compare the cause-specific hazard of MACE between treatments and estimate cumulative risk accounting for the competing risks of changing therapy or noncardiovascular death.
RESULTS: There were 67 749 metformin and 28 976 sulfonylurea persistent monotherapy users; the weighted cohort included 24 679 metformin and 24 799 sulfonylurea users (median age, 70 years [interquartile range {IQR}, 62.8-77.8]; 48 497 men [98%]; and 40 476 white individuals [82%], with median estimated glomerular filtration rate of 55.8 mL/min/1.73 m2 [IQR, 51.6-58.2] and hemoglobin A1c level of 6.6% [IQR, 6.1%-7.2%] at cohort entry). During follow-up (median, 1.0 year for metformin vs 1.2 years for sulfonylurea), there were 1048 MACE outcomes (23.0 per 1000 person-years) among metformin users and 1394 events (29.2 per 1000 person-years) among sulfonylurea users. The cause-specific adjusted hazard ratio of MACE for metformin was 0.80 (95% CI, 0.75-0.86) compared with sulfonylureas, yielding an adjusted rate difference of 5.8 (95% CI, 4.1-7.3) fewer events per 1000 person-years of metformin use compared with sulfonylurea use.
CONCLUSIONS AND RELEVANCE: Among patients with diabetes and reduced kidney function persisting with monotherapy, treatment with metformin, compared with a sulfonylurea, was associated with a lower risk of MACE.
参考来源
- Roumie CL, Chipman J, Min JY, et al. Association of Treatment With Metformin vs Sulfonylurea With Major Adverse Cardiovascular Events Among Patients With Diabetes and Reduced Kidney Function. JAMA. 2019. PMID: 31536102. doi:10.1001/jama.2019.13206
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。